Antifungal agent 151 is a Prp8 intein inhibitor that inhibits the self-splicing process of the Prp8 intein, preventing maturation of the Prp8 protein. Antifungal agent 151 exerts in vitro antifungal activity against Cryptococcus neoformans and Cryptococcus gattii. Antifungal agent 151 can be used for the research of cryptococcus pneumonia.

Antifungal agent 143 is potent antifungal agent which also exihibits antibacterial activity. Antifungal agent 143 inhibits growth of Candida albicans and Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pyogenes. Antifungal agent 143 can be used for antimicrobial research.

Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC50 values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer.

Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC50 value of 199 nM for Cyclin E1 and an IC50 value of 133 nM for pRB. Anticancer agent 302 can be used for tumor research.

Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.

Anticancer agent 285 is an orally active anticancer agent with highly effective and selective haspin-inhibiting IC50 = 18 nM) activity. Anticancer agent 285 can be used for the study of colorectal cancer[1].

Antibiotic adjuvant 4 (Compound 13) is an Antibiotic adjuvant and efflux pump inhibitor. Antibiotic adjuvant 4 exhibits potent efflux pump inhibitory activity. Antibiotic adjuvant 4 significantly downregulates virulence-related genes of Staphylococcus aureus when used alone or in combination with antibiotics. Antibiotic adjuvant 4 enhances the efficacy of Ciprofloxacin against multiagent-resistant Staphylococcus aureus strains.

Antibacterial agent 339 is an antibacterial agent. Antibacterial agent 339 inhibits the growth of Fusarium oxysporum f.sp.cubense Race 4 with a MIC of 50.5 μM. Antibacterial agent 339 shows low toxicity in Kunming mice. FLT3-IN-30 can be used for the research of banana wilt.

Antibacterial agent 332 is an inhibitor of DsbA from Escherichia coli (EcDsbA). Antibacterial agent 332 reduces the swarming motility of Escherichia coli without affecting bacterial growth. Antibacterial agent 332 can be used in the research of bacterial infections caused by Escherichia coli.

Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis.

Antibacterial agent 323 is an antifbacterial agent with weak activity. Antibacterial agent 323 can be used for the research of bacterial nfection, such as Acinetobacter baumannii strains.

Antifungal agent 147 (compound 2) is a lipophilic antibacterial agent with dark toxicity. Antifungal agent 147 shows a phototoxic effect on S. aureus and E. coli. Antifungal agent 147 can penetrate the bacterial cell membrane and disturb its structure, leading to dark toxicity. Antifungal agent 147 can be used for bacteria infection research.

Antibacterial agent 313 (Compound 20) is a broad-spectrum antibacterial agent. Antibacterial agent 313 can be used for research of bacterial infection.

Antibacterial agent 310 (compound 2) is a bis-benzimidazole-derived chelating ligand exhibiting antibacterial activity. Antibacterial agent 310 shows inhibition activity against intracellular viruses. Antibacterial agent can be used for antibacterial research.

Antibacterial agent 308 (Compound A25) is an antibacterial agent. Antibacterial agent 308 selectively targets bacterial membranes by binding phosphatidylethanolamine, thereby disrupting membrane polarization, elevating intracellular ROS levels. Antibacterial agent 308 shows significant anti-biofilm activity against S. aureus. Antibacterial agent 308 demonstrates potent anti-MRSA activity.

Anordrin is a contraceptive agent. Anordrin exhibits estrogenicites and can induce decrease in serum progesterone levels in rat models. Anordrin inhibits endometrial epithelial cell mitosis and NAFLD induced by Tamoxifen in mouse uterus and liver as an anti-estrogenic and estrogenic agent.

Androgen receptor degrader-6 is a blood-brain barrier-permeable AR degrader. Androgen receptor degrader-6 inhibits the chaperone activity of HSP27 and disrupts the HSP27-AR complex. Androgen receptor degrader-6 promotes the degradation of wild-type and mutant AR, reduces AR protein levels, and inhibits the growth of glioblastoma cells. Androgen receptor degrader-6 can be used in glioblastoma research.

Analgesic agent-4 is an adenosine A3AR ligand with analgesic/antinociceptive activity. Analgesic agent-4 inhibits writhing responses in mice and exhibits dose-dependent activity in the acetic acid-induced mouse writhing model. Analgesic agent-4 can be used in the research of pain-related diseases.

AN02 is a derivative of Curcumin. AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab, can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer.

AMYR/CTR agonist 1 (Compound 195) is a pancreatic amylin receptor and calcitonin receptor (AMYR/CTR) agonist with EC50 values for pancreatic amylin receptor and calcitonin receptor cAMP of 99.5 and 6.16 pM respectively. AMYR/CTR agonist 1 can be used in the research of diseases such as type 2 diabetes and obesity.

AMPK activator 18 is a potent allosteric activator of AMPK complexes containing the β2 isoform. AMPK activator 18activates α2-containing AMPK α2β2γ1 and α2β2γ3 complexes, with EC50 values of 17.2 and 82.1 nM. AMPK activator 18 stimulates β2-AMPK in cells, and glucose uptake by isolated skeletal muscle. AMPK activator 18 induces acetyl-coenzyme A carboxylase (ACC) and AMPK α-T172 phosphorylation. AMPK activator 18 can be used for the research of type 2 diabetes.

Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders.

Amonafide L-malate is a topoisomerase II inhibitor and DNA intercalator that induces Apoptotic signaling by blocking the binding of Topo II to DNA.

Amocarzine (CGP 6140) is an orally active antifilarial agent. Amocarzine can result in the swelling of mitochondrion and inhibit respiration and other associated metabolic functions. Amocarzine can be used for the research of infection.

Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi. Aminobutane bisphosphonate inhibits proliferation of intracellular amastigote Trypanosoma cruzi and lacks activity against non-infective epimastigote forms. Aminobutane bisphosphonate reduces osteoclastic bone resorption, osteoid surface extent, and osteoclast number per mm of bone surface.Aminobutane bisphosphonate alters mineral apposition rate in intact legs, inhibits immobilization-induced bone loss, and increases trabecular bone volume in Sprague-Dawley rats. Aminobutane bisphosphonate can be used for the research of american trypanosomiasis (chagas' disease) and immobilization-related bone loss.

Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE, and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma.

AMG410 diTFA is a non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D. AMG410 diTFA shows greater than 100-fold selectivity against both HRAS and NRAS. AMG410 diTFA is a dual GTP(on)- and GDP(off)-state inhibitor (Kd(GDP-state) of 1 nM; Kd(GTP-state) of 22 nM). AMG410 diTFA blocks KRAS signaling in a cycling state-independent manner and also blocks proliferation in wildtype KRAS-amplified tumor cells. AMG410 diTFA can be used for the study of colorectal, pancreatic, and lung cancers.

AMC-3-030 is a selective and potent dual inhibitor targeting HDAC6 and chymotrypsin-like proteasome with IC50 values of 884 and 4.17 nM. AMC-3-030 has a proliferation inhibitory effect. AMC-3-030 can reduce α-tubulin and β-actin levels. AMC-3-030 can be used for research of multiple myeloma.

AM-112 is a β-lactamase (β-lactamase) inhibitor and antibacterial agent, with IC50 values ranging from 0.0002 μg/mL to 0.67 μg/mL against class A, C, and D β-lactamase. By inhibiting PBP2, the penicillin-binding protein of E. coli, and protecting Ceftazidime from enzymatic hydrolysis, AM-112 significantly enhances the antibacterial efficacy of Ceftazidime against Gram-negative bacteria, enterococci, and staphylococci. AM-112 exhibits favorable pharmacokinetic properties and acid-base stability. AM-112 can be used for the research of bacterial infections.

ALX-5407 ((R)-NFPS) is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia.